BLACKLEDGER Selling Watch: CVNA, COIN, NFLX
BLACKLEDGER's latest selling watch update tracks CVNA, COIN, NFLX, EUR/USD, CRSP, NTLA from the active public watchlist. This post is built from public-safe status data, in-house public signal labels, and outside public source context. It is designed to help readers understand what is happening around each asset without exposing private research methods.
Selling Watch Data
The dedicated feed category for this update is Selling. The latest public scan timestamp is 2026-07-13T08:00:59.307120+00:00.
- CVNA (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- COIN (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- NFLX (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- EUR/USD (forex): Bear public bias, Extended, public score 8.3/10, status: Paper trading research.
- CRSP (stock): Bear public bias, Extended, public score 8.0/10, status: Paper trading research.
- NTLA (stock): Bear public bias, Extended, public score 8.0/10, status: Paper trading research.
- LCID (stock): Bear public bias, Extended, public score 8.0/10, status: Paper trading research.
- URG (stock): Bear public bias, A-List, public score 7.5/10, status: Paper trading research.
Educational Context: How To Use This Page
This page is not a trade instruction. It is an educational research brief. Readers can use it to understand company or project background, public market context, public status labels, and relevant outside-source headlines before doing their own due diligence.
CVNA Public Research Bio
Name: Carvana Co.. Market class: stock. Public bias: Bear. Public tier: Extended.
Carvana Co., together with its subsidiaries, operates an e-commerce platform for buying and selling used cars. It provides vehicle acquisition, inspection and reconditioning, online search and shopping experience, financing, complementary products, logistics network and distinctive fulfillment experience, and post-sale customer support services. The company also operates auction sites. Carvana Co. was founded in 2012 and is based in Tempe, Arizona.
- Latest public price/reference: $65.82
- Public market capitalization: $72.20B
- Recent public volume/reference: 4.70M
- One-month public movement: 1.01%
- Sector/category: Consumer Cyclical
Why CVNA Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Carvana (CVNA) is One of the Best Stocks to Invest in Under $100, Here’s Why — Insider Monkey
- Prediction: Carvana's New-Car Business Will Work. Early Numbers Are Stunning. — Motley Fool
- CVNA Stock Down 20% YTD: Is This a Buy the Dip Opportunity? — Zacks
- Carvana Co. (CVNA) Is a Trending Stock: Facts to Know Before Betting on It — Zacks
COIN Public Research Bio
Name: Coinbase Global, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.
Coinbase Global, Inc. operates platform for crypto assets in the United States and internationally. It provides the primary financial account in the crypto economy for consumers; a brokerage platform with a pool of liquidity across the crypto marketplace for institutions; and a suite of products granting access to build onchain for developers. The company was founded in 2012 and is based in New York, New York.
- Latest public price/reference: $159.1
- Public market capitalization: $41.91B
- Recent public volume/reference: 6.13M
- One-month public movement: 8.27%
- Sector/category: Financial Services
Why COIN Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Coinbase, Lyft, and Axon prove there's more going on in markets than the 'Magnificent 7' — Yahoo Finance
- Coinbase's Chief Policy Officer Tells Elizabeth Warren She Has CLARITY Act ‘Exactly Backward’ On National Security — Stocktwits
- Coinbase CEO Brian Armstrong Has a New Solution to America's $39 Trillion Debt Problem. (Hint: It Involves Bitcoin.) — Motley Fool
- Coinbase CEO has a bold take on internet's future beyond ads — TheStreet
NFLX Public Research Bio
Name: Netflix, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.
Netflix, Inc. provides entertainment services worldwide. The company offers television (TV) series, documentaries, feature films, games, and live programming across various genres and languages. It also provides members the ability to receive streaming content through a host of internet-connected devices, including TVs, digital video players, TV set-top boxes, and mobile devices. Netflix, Inc. was incorporated in 1997 and is headquartered in Los Gatos, California.
- Latest public price/reference: $73.38
- Public market capitalization: $308.95B
- Recent public volume/reference: 46.71M
- One-month public movement: -1.34%
- Sector/category: Communication Services
Why NFLX Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Here’s How Nancy Pelosi Beat the Stock Market and Warren Buffett — 24/7 Wall St.
- Netflix Is Losing Viewers To The World Cup. That May Be The Wrong Measure Of The Business. — Barchart
- Netflix Might Be Ready to Buy Something Again, but It's Not What You Think — Motley Fool
- 3 Reasons Why Netflix Has a Lot to Prove on July 16 — Motley Fool
EUR/USD Public Research Bio
Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.
Name: EUR/USD. Market class: forex. Public bias: Bear. Public tier: Extended.
Outside-source profile data was limited for this asset at publication time, so this section focuses on public BLACKLEDGER status data and verified public market context.
- Latest public price/reference: not available
- Public market capitalization: not available
- Recent public volume/reference: not available
- One-month public movement: not available
- Sector/category: not available
Why EUR/USD Is In This Public Update
- BLACKLEDGER public score is in the 7.0-8.9 confirmation band (the most reliable tier), so this asset receives a deep public bio and outside-source review.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- No fresh public headlines were available from the automated outside-source pull. The asset r[redacted]ins covered through public status data.
CRSP Public Research Bio
Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.
Name: CRISPR Therapeutics AG. Market class: stock. Public bias: Bear. Public tier: Extended.
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemog
- Latest public price/reference: $53.38
- Public market capitalization: $5.25B
- Recent public volume/reference: 2.07M
- One-month public movement: -4.23%
- Sector/category: Healthcare
Why CRSP Is In This Public Update
- BLACKLEDGER public score is in the 7.0-8.9 confirmation band (the most reliable tier), so this asset receives a deep public bio and outside-source review.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- CRISPR Therapeutics AG (CRSP) Stock Dips While Market Gains: Key Facts — Zacks
- 3 Reasons to Buy CRISPR Therapeutics Stock — Motley Fool
- NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock? — Zacks
- Vertex’s Crinetics Deal Balances Growth with Integration Risk — MarketBeat
NTLA Public Research Bio
Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.
Name: Intellia Therapeutics, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioed[redacted]. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeu
- Latest public price/reference: $14.21
- Public market capitalization: $1.99B
- Recent public volume/reference: 6.18M
- One-month public movement: -15.47%
- Sector/category: Healthcare
Why NTLA Is In This Public Update
- BLACKLEDGER public score is in the 7.0-8.9 confirmation band (the most reliable tier), so this asset receives a deep public bio and outside-source review.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Intellia Therapeutics (NTLA) Could Be 37% Undervalued After Phase 3 Lonvo Z Success — Simply Wall St.
- NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock? — Zacks
- Intellia Therapeutics (NTLA) Stock Looks Rich On Sales But Weak On Returns — Simply Wall St.
- Wall Street Doubles Down on Wolfspeed Short Positions Over Cash Burn Fears — Barchart
What The Public Data Shows
The public feed highlights ticker status, market class, directional bias, score, tier, confidence, company or project profile, public market references, and outside-source headlines. These fields support a deeper view of BLACKLEDGER's public research feed while keeping private methods undisclosed.
Why This Category Matters
The Selling section gives readers a focused path through the market: buying watch content for constructive candidates, selling watch content for defensive movement, investing content for higher-quality public watch names, and market trend notes for broader context.
Research-Only Notice
BLACKLEDGER content is market research only. There is no live execution signal, no recommendation to buy or sell, and no financial advice. Readers should perform their own due diligence and consult licensed professionals before making financial decisions.
Research-only. No execution signal. Not financial advice.